T2D and cardiovascular diseases (CVD) share common risk factors, including obesity and hyperglycemia. The primary difference lies in LDL-C levels: elevated LDL-C is causally linked to CVD but not to T2D risk. T2D is a significant risk factor for CVD, and CVD often precedes T2D development. While statins are widely used to prevent cardiovascular events due to their ability to lower LDL-C, they are also associated with an increased risk of T2D. Statins raise fasting glucose and HbA1c concentrations.
Researchers from the University of Eastern Finland summarized clinical and population studies and meta-analyses to explore how statins affect T2D risk, the differences among statins, and the mechanisms and genetic factors influencing T2D development with statin use.
Types of Statins
- Lovastatin – approved in 1987
- Simvastatin and Pravastatin – approved in 1991
- Fluvastatin – approved in 1994
- Atorvastatin – approved in 1997
- Rosuvastatin – approved in 2003
- Pitavastatin – approved in 2009
The maximum doses of rosuvastatin, atorvastatin, and simvastatin lower LDL-C by 50-60%, lovastatin by 50%, and pravastatin and fluvastatin by 30-40%.
Statins and T2D Risk
Early Studies:
- Pravastatin: A 2001 study indicated that pravastatin reduced T2D risk by 30%. However, a 2002 study found no significant increase or decrease in T2D incidence, though pravastatin reduced coronary heart disease risk by 19%.
- Atorvastatin and Simvastatin: These statins increase glucose and HbA1c levels, elevating the risk of T2D.
- Rosuvastatin: This statin reduces cardiovascular event incidence by 44% but raises T2D risk by 26%.
Early studies showed that statins increase T2D risk by 9-12%. High-intensity statins such as rosuvastatin, atorvastatin, and simvastatin are associated with higher risk than moderate-intensity statins like pravastatin and pitavastatin. Higher doses further increase T2D risk. A 2019 meta-analysis suggested an even greater T2D risk—up to 55%, mainly with high-intensity statins.
Mansi et al. investigated the link between initiating statin therapy and diabetes progression. Patients taking statins were more likely to require insulin therapy, experience severe hyperglycemia, and need additional glucose-lowering medications. High-intensity statins were linked to a greater likelihood of diabetes progression.
Genetic Factors
- HMGCR Gene: Encodes HMG-CoA reductase, the enzyme regulating cholesterol synthesis. Statins inhibit this enzyme, reducing cholesterol production. The HMGCR gene variant rs17238484-G increases T2D risk by 2-6%, affecting insulin sensitivity and secretion.
- SLCO1B1 Gene: Related to statin transport in the liver, this gene showed no significant association with T2D, elevated glucose levels, insulin resistance, or impaired insulin secretion.
- LDLR Gene: A gene mutation associated with familial hypercholesterolemia reduces T2D risk in individuals with higher LDL-C levels.
Mechanisms Leading to T2D with Statin Use
Statins increase glucose levels within 12 weeks.
LDL-C plays a critical role in β-cell dysfunction. Statins inhibit cholesterol synthesis via the HMG-CoA reductase pathway, leading to cholesterol accumulation in pancreatic β-cells, impairing their function.
Statins reduce insulin sensitivity by 24% and insulin secretion by 12%. Initially, β-cells compensate for insulin resistance by producing more insulin. However, the pancreas cannot sustain compensation over time, leading to reduced insulin secretion and T2D development.
Conclusions and Clinical Implications
Statins effectively lower LDL-C levels and reduce the risk of cardiovascular events, including myocardial infarction and stroke. Over five years, statin therapy prevents major cardiovascular events in 10% of high-risk patients (1,000 out of 10,000) and 5% of moderate-risk patients (500 out of 10,000). There are no substantial differences in cardiovascular outcomes among simvastatin, fluvastatin, lovastatin, atorvastatin, rosuvastatin, and pravastatin.
Adverse effects of statin therapy include myopathy (muscle pain or weakness), T2D, and hemorrhagic strokes. Statin treatment of 10,000 patients over five years results in approximately 5 cases of myopathy, 50-100 new T2D cases, and 5-10 hemorrhagic strokes.
Statins are effective not only in reducing CVD risk but also in mitigating microvascular complications. Diabetic patients treated with statins experienced a 40% lower risk of diabetic retinopathy, a 34% lower risk of diabetic neuropathy, and a 12% lower risk of foot gangrene compared to those not taking statins. However, statins did not reduce the risk of diabetic nephropathy.
While statins increase the likelihood of developing T2D, their benefits in preventing cardiovascular events significantly outweigh the potential risks. The risk of T2D should not warrant discontinuing statin therapy. To minimize T2D risk during statin use, it is essential to address risk factors such as obesity, hypertension, high triglyceride levels, and smoking. A healthy lifestyle can help prevent T2D.
Useful article, necessary information? Share it!
Someone will also find it useful and necessary:
Reference
Statins and risk of type 2 diabetes: mechanism and clinical implications
